Comparative effectiveness of nivolumab versus clinical practice for advanced gastric or gastroesophageal junction cancer
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: To determine the effectiveness of nivolumab compared with routine clinical practice (RCP) for patients with gastric or gastroesophageal cancer refractory to, or intolerant of, two or more previous regimens, using real-world electronic patient records from a US population, a single-arm trial (CheckMate 032) and a randomized controlled trial in an Asian setting (ATTRACTION-2). Materials & methods: A simulated treatment comparison was conducted to predict overall survival for patients treated with nivolumab compared with RCP in the USA. Results: Results of the indirect simulated treatment comparison suggest that nivolumab is associated with a 50% reduction in the risk of all-cause mortality relative to RCP (Hazard ratio: 0.50; 95% CI: 0.36, 0.68). Conclusion: The survival benefit of nivolumab may extend more generally to the USA.
Supplementary Material
File (cer-2019-0145_suppl.docx)
- Download
- 2.91 MB
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Qi X, Liu Y, Wang W. Management of advanced gastric cancer: an overview of major findings from meta-analysis. Oncotarget 7(47), 78180–78205 (2016).
2.
Qiu M-Z, Cai M-Y, Zhang D-S et al. Clinicopathological characteristics and prognostic analysis of Lauren classification in gastric adenocarcinoma in China. J. Transl. Med. 11(1), 58 (2013).
3.
Gill S, Shah A, Le N, Cook EF, Yoshida EM. Asian ethnicity-related differences in gastric cancer presentation and outcome among patients treated at a canadian cancer center. J. Clin. Oncol. 21(11), 2070–2076 (2003).
4.
Hsu C, Shen Y-C, Cheng C-C, Cheng A-L, Hu F-C, Yeh K-H. Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: a meta-analysis and meta-regression. Gastric Cancer 15(3), 265–280 (2012).
5.
Lin SJ, Gagnon-Bartsch JA, Tan IB et al. Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Gut 64(11), 1721–1731 (2015).
6.
Janjigian YY, Bendell J, Calvo E et al. CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J. Clin. Oncol. 36(28), 2836–2844 (2018).
7.
Kang YK, Boku N, Satoh T et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, Phase III trial. Lancet 390(10111), 2461–2471 (2017).
• Summarizes the results of a randomized controlled trial of nivolumab in patients with gastric cancer.
8.
Janjigian YY, Le DT, Ott PA et al. Survival of chemotherapy (chemo) refractory gastric or gastroesophageal junction cancer (GC/GEJC) patients from Flatiron Health (FH): matched clinical characteristics to ATTRACTION-2 and CHECKMATE-032. J. Clin. Oncol. 36(Suppl. 4), 51–51 (2018).
9.
Benchimol EI, Smeeth L, Guttmann A et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLoS Med. 12(10), e1001885 (2015).
10.
Von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370(9596), 1453–1457 (2007).
11.
Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. NICE DSU Technical Support Document 18: methods for population-adjusted indirect comparisons in submission to NICE (2016). http://nicedsu.org.uk/wp-content/uploads/2017/05/Population-adjustment-TSD-FINAL.pdf
12.
Ott P, Calvo E, Sharma P et al. Nivolumab monotherapy in patients with advanced gastric or gastroesophageal junction (GEJ) cancer and 2 or more prior treatment regimens: sub-analysis of the CheckMate 032 study. Ann. Oncol. 28(Suppl. 3), mdx262.006-mdx262.006 (2017).
13.
Janjigian YY, Le DT, Alexander P et al. Survival of chemotherapy (chemo) refractory gastric or gastroesophageal junction cancer (GC/GEJC) patients from Flatiron Health (FH): matched clinical characteristics to ATTRACTION-2 and CHECKMATE-032. Presented at: Gastrointestinal Cancers Symposium. San Francisco, CA, USA (Jan 18–20, 2018).
14.
Rebora P, Salim A, Reilly M. bshazard: a flexible tool for nonparametric smoothing of the hazard function. R Journal 6(2), 114–122 (2014).
15.
Jansen JP. Network meta-analysis of survival data with fractional polynomials. BMC Med. Res. Methodol. 11, 61 (2011).
16.
Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav. Res. 46(3), 399–424 (2011).
17.
Rebora P, Salim A, Reilly M. bshazard: nonparametric smoothing of the hazard function. R package version 1.1 (2018). https://CRAN.R-project.org/package=bshazard
18.
Therneau T. A package for survival analysis in S (2015). https://CRAN.R-project.org/package=survival
19.
Plummer M. JAGS: a program for analysis of Bayesian graphical models using Gibbs sampling (2003). https://www.r-project.org/conferences/DSC-2003/Proceedings/Plummer.pdf
20.
Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 326(7382), 219 (2003).
21.
NCCN. Guidelines V1.2018 gastric cancer (2018). https://www.nccn.org/professionals/physician_gls/default.aspx
22.
Fuchs CS, Doi T, Jang RW et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase II Clinical KEYNOTE-059 Trial. JAMA Oncol. 4(5), e180013 (2018).
23.
FDA. Summary review; application number 125514Orig1s024 (2017). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/125514Orig1s024Approv.pdf
24.
Chau I. Checkpoint inhibition: an ATTRACTION in advanced gastric cancer? Lancet 390(10111), 2418–2419 (2017).
25.
Kang Y-K, Boku N, Satoh T et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, Phase III trial. Lancet 390(10111), 2461–2471 (2017).
26.
Shitara K, Özgüroğlu M, Bang Y-J et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, Phase III trial. Lancet 392(10142), 123–133 (2018).
27.
FDA. Framework for FDA's real-world evidence program (2018). https://www.fda.gov/media/120060/download
•• Overview of the US FDA’s views on the use of real-word data and evidence.
28.
Ishak KJ, Proskorovsky I, Benedict A. Simulation and matching-based approaches for indirect comparison of treatments. Pharmacoeconomics 33(6), 537–549 (2015).
• Overview of techniques for indirect treatment comparisons.
29.
Faria R, Hernandez Alava M, Manca A, Wailoo A. NICE DSU technical support document 17: the use of observational data to inform estimates of treatment effectiveness in technology appraisal: methods for comparative individual patient data (2015). http://nicedsu.org.uk/technical-support-documents/observational-data-tsd/
30.
Choi J. Prognostic factor for third-line chemotherapy in patients with advanced gastric cancer. J. Clin. Oncol. 35(Suppl. 15), e15702–e15702 (2017).
• Examination of prognostic factors in the population of gastric cancer patients.
31.
Shim HJ, Yun JY, Hwang JE, Bae WK, Cho SH, Chung IJ. Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer. Gastric Cancer 14(3), 249–256 (2011).
Information & Authors
Information
Published In
Pages: 103 - 114
PubMed: 31872771
Copyright
© 2019 The authors. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 27 September 2019
Accepted: 27 November 2019
Published online: 24 December 2019
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Comparative effectiveness of nivolumab versus clinical practice for advanced gastric or gastroesophageal junction cancer. (2019) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2019-0145
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Stefan Tatalovic, Bernhard Doleschal, Alexander Kupferthaler, Stephan Grundner, Jonathan Burghofer, Gerald Webersinke, Simon Schwendinger, Emina Jukic, Johannes Zschocke, Lorenz Danhel, Antonia Kirchweger, Lukas Havranek, Demetre Shalamberidze, Daniel Rezaie, Matthias Biebl, Holger Rumpold, Patrick Kirchweger, Circulating Tumor DNA (ctDNA) Dynamics Predict Early Response to Treatment in Metastasized Gastroesophageal Cancer (mGEC) After 2 Weeks of Systemic Treatment, Cancers, 10.3390/cancers16233960, 16, 23, (3960), (2024).
- Chenglong Wang, Tongze Cai, Jiangcun Wei, Ying Huang, Lin Xiao, Tong Li, Zujie Qin, Efficacy and safety of first-line immune checkpoint inhibitor combination therapies in patients with advanced esophageal squamous cell carcinoma: a network meta-analysis, Frontiers in Oncology, 10.3389/fonc.2024.1369848, 14, (2024).
- Levent Kaptanoglu, Yalcin Burak Kara, Esophageal Ca Staging and Management According to Current Guidelines, Risk Factors and Therapy of Esophagus Cancer, 10.1007/978-3-031-47024-0_19, (339-352), (2024).
- Julie E. Park, Harlan Campbell, Kevin Towle, Yong Yuan, Jeroen P. Jansen, David Phillippo, Shannon Cope, Unanchored Population-Adjusted Indirect Comparison Methods for Time-to-Event Outcomes Using Inverse Odds Weighting, Regression Adjustment, and Doubly Robust Methods With Either Individual Patient or Aggregate Data, Value in Health, 10.1016/j.jval.2023.11.011, 27, 3, (278-286), (2024).
- Marie‐Noelle Kronig, Marc Wehrli, Diego Salas‐Benito, Marcela V. Maus, “Hurdles race for CAR T ‐cell therapy in digestive tract cancer” , Immunological Reviews, 10.1111/imr.13273, 320, 1, (100-119), (2023).
- Imtiaz A. Samjoo, Luisa Klotz, Gavin Giovannoni, Christopher Drudge, Anja Haltner, Evelyn Worthington, Melody Zhao, Róisín Brennan, Dieter A. Häring, Chris Cameron, Nicholas Adlard, Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis, Multiple Sclerosis and Related Disorders, 10.1016/j.msard.2022.104031, 66, (104031), (2022).
- R. Obermannová, M. Alsina, A. Cervantes, T. Leong, F. Lordick, M. Nilsson, N.C.T. van Grieken, A. Vogel, E.C. Smyth, Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, Annals of Oncology, 10.1016/j.annonc.2022.07.003, 33, 10, (992-1004), (2022).
- Satoshi Hibi, Yuko Shirokawa, Kengo Nanya, Yuko Kato, Nobuto Ito, Takae Kataoka, Takashi Yoshida, Yoshiaki Marumo, Satoshi Kayukawa, Shu Yuasa, Yoshiteru Tanaka, Kenji Ina, Application of the Plan-Do-Check-Act Cycle for Managing Immune-Related Adverse Events, Journal of Analytical Oncology, 10.30683/1927-7229.2021.10.06, 10, (61-68), (2021).